'The big surprise here is the efficacy': UBS's Stuart Kaiser on market reaction to Pfizer vaccine reports

Stuart Kaiser, UBS Head of Equity Derivatives Research, joined Yahoo Finance Live to discuss today’s market action as investors digest the election results and COVID-19 vaccine news from Pfizer. …read more

Source:: Yahoo Finance


Did you enjoy this article? Join our FREE Newsletter!
I agree to have my personal information transfered to MailChimp ( more information )
Join over 100,000 investors and business leaders worldwide. Get the latest actionable business and investing intelligence before the rest of the crowd.
We hate spam. Your email address will not be sold or shared with anyone else.